Newsroom | 5956 results

ST. LOUIS--(BUSINESS WIRE)--The U.S. Food & Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2® test, providing patients and health care professionals with an accurate, accessible, and scalable blood test to help diagnose Alzheimer’s disease in conjunction with standard clinical workup. An estimated 19-20 million U.S. adults aged 65 and older, and hundreds of thousands more between ages 45 and 65 are living with cognitive impairment and may benefit from an early diagnosis1....

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, from August 28-31, 2026. Key Facts Data from two late-breaking presentations will be featured, including a pre-specified subgroup analysis from the Phase III FIND-CKD trial, which evaluated KERENDIA® (finerenone) in patients with CK...

BLUE BELL, Pa.--(BUSINESS WIRE)--Mitochon Pharmaceuticals is pleased to announce the receipt of a $1 million Hoffman ALS Clinical Trial Award from the ALS Association. This funding will pave the way for a 24-week sporadic ALS study and expand upon recent clinical studies in Europe showing a quick drop in Neurofilament Light (NfL) in sporadic ALS participants taking MP-101 capsules. MP-101 is a First-in-Class oral, brain penetrating small molecule that enhances mitochondrial function by correcti...

PHILADELPHIA--(BUSINESS WIRE)--iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the sh...

WACO, Texas--(BUSINESS WIRE)--ProCare Injury Specialists today opened its 14th location, a new clinic in Waco, Texas, continuing its expansion to provide comprehensive care for accident and injury patients across the state. Waco sits at the midpoint of one of the busiest stretches of highway in Texas. I-35 carries commuter, commercial, and university traffic through McLennan County every day, and years of construction along the corridor have kept congestion and collisions high. Preliminary cras...

DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics appointed veteran pharmacogenomics leader and former St. Jude CEO Dr. William Evans to guide BioSkryb’s next phase of growth...

ALBANY, N.Y.--(BUSINESS WIRE)--The Regenerative Research Foundation today announced that its Neural Stem Cell Institute (NSCI) has been named a Phase 1 winner in the National Institute of Health’s (NIH) Complement-ARIE Reduction to Practice (RTP) Challenge. The Complement-ARIE RTP Challenge, sponsored by the NIH in partnership with the National Aeronautics and Space Administration (NASA) Tournament Lab, supports the development of New Approach Methodologies (NAMs). NAMs are advanced human-based...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are bein...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026...